DASATINIB TEVA 50 mg, film-coated tablet 60 tablets
Active ingredients: Dasatinib, Dasatinib monohydrate
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet60 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- DASATINIB TEVA 50 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- 60 plaquette(s) OPA : polyamide orienté aluminium PVC-Aluminium de 1 comprimé
- Marketing authorisation holder
- TEVA (PAYS-BAS)
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 30 Jul 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Initial prescription by a hospital doctor
- Initial prescription by a specialist
- Renewal by a specialist only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
68495604CIP73016924CIP133400930169247Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| DASATINIB MONOHYDRATÉcomprimé | — | SA |
| DASATINIBcomprimé | 50 mg · un comprimé | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.